Assessing disease burden in patients with classic MPNs

Holly Geyer, Ruben A. Mesa

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Myeloproliferative neoplasm (MPN) disorders including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), are recognized amongst the world of malignancies for their unique diseaseeburden profiles. Symptom management remains a prime directive for all MPN disorders. Limited by the dramatic heterogeneity and disparate severity amongst symptoms, only recently have researchers possessed the scoring tools necessary to quantify the MPN symptom burden and investigate its role in patient prognosis. In addition to symptom management, clinicians are also tasked with managing the numerous complications that arise from MPN progression including splenomegaly, cytopenias, thrombotic and hemorrhagic events and transformation to MF (from PV or ET) or acute myelogenous leukemia. In this article, we discuss the pleiotropic solidarity of the MPN symptom profile, inherent complications that define the disorders, available patientreported outcome tools, the role of risk-scoring algorithms and open arenas for ongoing MPN symptom research.

Original languageEnglish (US)
Pages (from-to)107-119
Number of pages13
JournalBest Practice and Research: Clinical Haematology
Issue number2
StatePublished - 2014


  • Essential thrombocythemia
  • Myelofibrosis
  • Myeloproliferative neoplasm
  • Polycythemia vera
  • Risk
  • Symptom

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry


Dive into the research topics of 'Assessing disease burden in patients with classic MPNs'. Together they form a unique fingerprint.

Cite this